CB-839, a small molecule inhibitor of GLS1, is used in combination with erlotinib to inhibit the growth of EGFR-mutated NSCLC and with Glutor, an inhibitor of the glucose transporter GLUT1/2/3, to suppress colon cancer cell growth [187, 188]. This evidence concerns the gene GLS and non-small cell lung carcinoma.